Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells

被引:34
作者
Xiao, YX [1 ]
Baydyuk, M [1 ]
Wang, HP [1 ]
Davis, HE [1 ]
Kellar, KJ [1 ]
机构
[1] Georgetown Univ, Sch Med, Dept Pharmacol, Washington, DC 20057 USA
关键词
D O I
10.1016/j.bmcl.2003.09.105
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The binding affinities of agonists at heteromeric nicotinic receptors composed of rat alpha2, alpha3 and alpha4 subunits in combination with beta2 or beta4 subunits were examined in stably transfected HEK 293 cells. In most cases, the affinities of agonists were higher at receptors composed of an alpha subunit in combination with the beta2 subunit than the beta4 subunit, and in some cases this difference was quite large (>250 times), suggesting the possibility of developing subtype-selective ligands and therapeutically useful drugs. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1845 / 1848
页数:4
相关论文
共 17 条
[1]   Differential regulation of nicotinic acetylcholine receptors in PC12 cells by nicotine and nerve growth factor (Reprinted from Soc Neurosci Abstr, vol 26, pg 373, 2000) [J].
Avila, AM ;
Dávila-García, MI ;
Ascarrunz, VS ;
Xiao, YX ;
Kellar, KJ .
MOLECULAR PHARMACOLOGY, 2003, 64 (04) :974-986
[2]  
BADIO B, 1994, MOL PHARMACOL, V45, P563
[3]   REGIONS OF BETA-2 AND BETA-4 RESPONSIBLE FOR DIFFERENCES BETWEEN THE STEADY-STATE DOSE-RESPONSE RELATIONSHIPS OF THE ALPHA-3-BETA-2 AND ALPHA-3-BETA-4 NEURONAL NICOTINIC RECEPTORS [J].
COHEN, BN ;
FIGL, A ;
QUICK, MW ;
LABARCA, C ;
DAVIDSON, N ;
LESTER, HA .
JOURNAL OF GENERAL PHYSIOLOGY, 1995, 105 (06) :745-764
[4]   CLASSIFICATION OF SKIN ALKALOIDS FROM NEOTROPICAL POISON-DART FROGS (DENDROBATIDAE) [J].
DALY, JW ;
BROWN, GB ;
MENSAHDWUMAH, M ;
MYERS, CW .
TOXICON, 1978, 16 (02) :163-188
[5]  
DavilaGarcia MI, 1997, J PHARMACOL EXP THER, V282, P445
[6]   REGIONS OF BETA-4.BETA-2 SUBUNIT CHIMERAS THAT CONTRIBUTE TO THE AGONIST SELECTIVITY OF NEURONAL NICOTINIC RECEPTORS [J].
FIGL, A ;
COHEN, BN ;
QUICK, MW ;
DAVIDSON, N ;
LESTER, HA .
FEBS LETTERS, 1992, 308 (03) :245-248
[7]  
FLORES CM, 1992, MOL PHARMACOL, V41, P31
[8]  
GERZANICH V, 1995, MOL PHARMACOL, V48, P774
[9]  
Harvey SC, 1996, J NEUROSCI, V16, P3798
[10]  
Hernandez S. C., 1999, Society for Neuroscience Abstracts, V25, P980